AbbVie: Q3 Earnings Snapshot

AbbVie lifts profit forecast as immunology drugs continue to fuel growth

AbbVie in Charts:Skyrizi and Rinvoq continue double-digitY/Y expansion

AbbVie in Charts: Skyrizi and Rinvoq continue double-digit Y/Y expansion in Q3 ’26; Humira falls 31%

AbbVie: Q3 Earnings Snapshot

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported third-quarter earnings of $4.22 billion.

AbbVie Reports Third-Quarter 2026 Financial Results

Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per Share Related to Acquired…

AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again

AbbVie stock slipped slightly Friday, but the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi. The post AbbVie's…

AbbVie Raises Full-Year Guidance as Non-GAAP EPS Beats Estimates

Third-quarter revenue reached $17.4 billion, up 10.3% year over year, while the immunology portfolio generated $9.165 billion in global net revenue.